Ventricular Ectopy Management

Introduction to Ventricular Ectopy

• Ventricular ectopy may be benign in structurally normal hearts but has prognostic significance in patients with underlying cardiac disease 1
• Patients with ventricular ectopy should undergo cardiac evaluation to exclude structural heart disease 1

Risk Assessment and Prognosis

• Isolated PVCs in the absence of heart disease generally do not have adverse prognostic significance, but frequent ventricular ectopy may lead to cardiomyopathy in some cases 1
• Beta-blockers are often first-line therapy for symptomatic ventricular ectopy, and patients with ventricular arrhythmias should undergo comprehensive cardiac evaluation to exclude structural heart disease 1, 2

Management of Ventricular Ectopy

• Lifestyle modifications with diet and exercise are recommended as first-line therapy, as per the American Diabetes Association guidelines, with a strength of evidence based on clinical trials 3
• Beta-blockers are often used to manage symptomatic ventricular ectopy 1, 2

Weight Loss Management in Patients with Ventricular Ectopy

• Phentermine is associated with increased cardiovascular risks, including palpitations and potential ischemic events, and is only approved for short-term use (≤12 weeks) by the FDA, with a recommended dosing of 8 mg taken three times daily (Lomaira) or 37.5 mg once daily (standard formulation) for weight loss management 4, 5, 6, 7
• The American College of Cardiology and other guideline societies recommend that patients with certain health conditions, such as history of heart disease, uncontrolled hypertension, glaucoma, hyperthyroidism, anxiety disorders, and history of drug abuse, should not use phentermine due to significant safety concerns, including increased heart rate and blood pressure 4
• Alternative weight loss medications, such as naltrexone/bupropion, orlistat, and lorcaserin, may be considered for patients with contraindications to phentermine, as recommended by the American Diabetes Association and American Heart Association 5, 8, 9
• GLP-1 receptor agonists, such as semaglutide and tirzepatide, are recommended for long-term weight management, especially in patients with cardiovascular disease, as suggested by the American Diabetes Association and American Heart Association 10, 3, 11
• The American Diabetes Association recommends monitoring blood pressure and heart rate every 2 weeks during the first 12 weeks, with efficacy and safety assessment at least monthly for the first 3 months, to minimize potential cardiovascular risks, and gradual tapering when discontinuing phentermine to minimize withdrawal effects, with a suggested tapering schedule:

• Phentermine may interact with serotonergic drugs, MAO inhibitors, and other stimulants, including ADHD medications like Adderall, and may require dose adjustment of insulin or oral hypoglycemic medications in diabetic patients, as recommended by the American Diabetes Association 10, 12, 9